VTI Overview

Sales Growth: For the first 31 weeks of the fiscal year, net sales reached $173.26 billion, marking a 9.1% increase from the previous year's $158.87 billion.

March Sales Performance: Comparable sales for the five-week retail March period rose by 9.4%, while the 31-week period saw a 7.2% increase, despite having one fewer shopping day due to the Easter holiday shift.

Wholesale and E-commerce Trends: Costco reported an 11% growth in net sales for March, totaling $28.41 billion, with e-commerce sales increasing by 22.5%, excluding certain factors.

Stock Market Sentiment: Retail sentiment around Costco's stock shifted positively, with 23 out of 37 analysts rating it as a 'Buy' or higher, reflecting a nearly 13% gain over the past 12 months.

Company Announcement: STAAAR Surgical announced its preliminary net sales expectations ahead of its quarterly earnings, anticipating over $90 million, significantly higher than previous estimates of $67.59 million.

Sales Performance: The company reported a net sales increase driven primarily by growth in China, its largest market, despite facing challenges in the Middle East and other regions due to geopolitical and macroeconomic issues.

Inventory Management: STAAAR has managed excess inventory by shipping minimal quantities of certain products to China, aligning inventory levels with targeted ranges.

Market Reaction: Following the announcement, STAAAR's stock saw a significant increase, shifting from bearish to bullish sentiment among retail investors, with hopes for revised price targets.

Stock Price Reaction: Shares of Assertio Holdings, Inc. (ASRT) fell 1.5% after the announcement of an agreement to be acquired by Garda Therapeutics for $125.1 million in cash.

Acquisition Details: Under the deal, Garda will pay Assertio shareholders $18 per share in cash, which represents a 3% discount to the stock's closing price on Tuesday.

Transaction Timeline: The acquisition is expected to close in the second quarter of 2026, subject to customary closing conditions.

Further Updates: Investors can follow updates on this developing story directly on Stocktwits.

Tesla Semi Production Timeline: Tesla's full-size Class 8 electric truck, the Semi, is set to begin volume production in the first half of 2026, with vehicle deliveries expected to start this year, expanding Tesla's offerings for commercial customers.

Pricing and Competition: The 500-mile version of the Tesla Semi is quoted at $290,000, which is higher than the initial announcement but still below the industry average for Class 8 electric trucks, amidst rising competition from startups like Windrose.

Vehicle Variants and Range: The Tesla Semi will be available in two variants: standard range (approximately 325 miles) and long range (about 500 miles), with the dedicated factory in Nevada currently in the tooling phase.

Market Sentiment and Stock Performance: Tesla's stock has remained in a bearish territory recently, despite gaining 54% over the past year, reflecting mixed retail sentiment and ongoing challenges in the electric truck market.

FDA Response: The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for advanced melanoma treatment, indicating it cannot approve the application in its current form due to inadequate clinical trial evidence.

Company's Actions: Following the FDA's feedback, Replimune resubmitted its application in October with additional data and analyses, aiming for a decision by April 10.

Stock Market Reaction: Shares of Replimune Group Inc. fell 15% as the FDA's decision deadline approached, reflecting negative sentiment among retail traders regarding the stock.

Future Outlook: Retail sentiment around REPL stock shifted from bullish to neutral, with concerns that the FDA might require a fresh trial for approval, potentially impacting the stock's value significantly.

Chegg Inc. Share Surge: Chegg Inc. (CHGG) shares increased nearly 16% following a letter from significant shareholder Galloway Capital Partners, which highlighted a disconnect between the company's market price and its intrinsic value.

Financial Health Assessment: Galloway Capital stated that Chegg maintains a strong balance sheet, expects to end the year with net cash and no debt, and sees no credible risk of financial distress.

Market Mispricing Concerns: The letter expressed concerns that the market is incorrectly pricing Chegg as if it is in financial distress, despite the company's solid financial standing.

Retail Sentiment: At the time of writing, retail sentiment around Chegg was trending in a bullish territory, indicating positive investor outlook.